75%Confidence
0Views
FDASource
2026-04-12Date
Summary
Amerisource Health Services faces a Class II recall for Meclizine tablets due to failed specifications, indicating potential quality control lapses in its distribution network. This may affect the reliability of Amerisource's generic drug supply and could lead to contractual penalties with retail partners.
Actionable: Review Amerisource's recent quality control metrics and assess any potential impact on its distribution agreements.
AI Confidence: 75%
Data Points
firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionU.S. Nationwide
productMeclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Dis
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now